Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3901961 in Advanced Synovial Sarcoma, MRCLS, or NSCLC
NCT06048705Phase 1Terminated
- Sponsor
- Adaptimmune Therapeutics
- Start
- Mar 2021
- Primary completion
- Jun 2023
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of NY-ESO-1/LAGE-1a TCR-engineered T cells in synovial sarcoma (SS), myxoid round cell liposarcoma (MRCLPS) and non-small cell lung cancer (NSCLC), sponsored by Adaptimmune Therapeutics. Primary endpoints: Number of Participants With Dose Limiting Toxicities up to 28 days, Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events up to 21 months and 1 more. Started Mar 2021; status: terminated.
02
Drugs
NY-ESO-1/LAGE-1a TCR-engineered T cells
03
Conditions
synovial sarcoma (SS)myxoid round cell liposarcoma (MRCLPS)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06048705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06048705.